Antares Pharma, Inc. (ATRS)

[Ghart]

This quote from Bob Apple on the last C.C:

"Our fourth collaboration with Teva is an epinephrine pen which is a generic form of Mylan's EpiPen. Teva received a complete response letter in February of 2016 and we have been working with them to formulate responses to the FDA questions. I'm happy to report that Teva has submitted their responses to the CRL and is working with the FDA toward a potential approval. Teva's guidance continues to be - that they will be able to launch an AV rated version of EpiPen in late 2017 or early 2018."

You can go to Seeking Alpha to read the entire conference call. Teva has also stated all questions have been answered and submitted. They did not publicly say what date but at the latest would have been sometime in February since all this came out beginning of March.